Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial
Abstract Background There are limited data on uninterrupted anticoagulation with direct oral anticoagulants during catheter ablation for atrial fibrillation (AF), particularly in Japan. We planned a subgroup analysis of the RE‐CIRCUIT study, comparing the use of uninterrupted dabigatran therapy with...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-04-01
|
| Series: | Journal of Arrhythmia |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/joa3.12024 |
| _version_ | 1818017259187077120 |
|---|---|
| author | Yukihiko Yoshida Masato Watarai Kenshi Fujii Wataru Shimizu Kazuhiro Satomi Yasuya Inden Yoshimasa Murakami Masato Murakami Atsushi Iwasa Masaomi Kimura Nobuko Yamada Tomofumi Nakagawa Matias Nordaby Ken Okumura |
| author_facet | Yukihiko Yoshida Masato Watarai Kenshi Fujii Wataru Shimizu Kazuhiro Satomi Yasuya Inden Yoshimasa Murakami Masato Murakami Atsushi Iwasa Masaomi Kimura Nobuko Yamada Tomofumi Nakagawa Matias Nordaby Ken Okumura |
| author_sort | Yukihiko Yoshida |
| collection | DOAJ |
| description | Abstract Background There are limited data on uninterrupted anticoagulation with direct oral anticoagulants during catheter ablation for atrial fibrillation (AF), particularly in Japan. We planned a subgroup analysis of the RE‐CIRCUIT study, comparing the use of uninterrupted dabigatran therapy with warfarin therapy during catheter ablation among the Japanese subgroup and with that in the total population. Methods The RE‐CIRCUIT study utilized a prospective, randomized, open‐label, blinded endpoint design, and the primary endpoint was the incidence of major bleeding events (MBEs). Patients were randomized to uninterrupted dabigatran 150 mg twice daily or warfarin. In this study, we analyzed the results in Japanese patients. Results Of 704 enrolled patients in the study, 112 Japanese patients were randomized to dabigatran (n = 65) or warfarin (n = 47). MBEs were experienced by two patients: one in the dabigatran group (1.6%, cardiac tamponade) and one in the warfarin group (2.2%, groin hematoma) (risk difference vs warfarin −0.6%; 95% CI −5.8, 4.7). Within the Japanese subgroup, there were no thromboembolic events in both groups. Conclusion While not designed to show statistical difference between two treatment groups, our results from the Japanese subgroup supported those from the overall population. Furthermore, this study provided clinical information regarding MBE, especially cardiac tamponade, in Japanese patients. |
| first_indexed | 2024-04-14T07:24:55Z |
| format | Article |
| id | doaj.art-c18fedcf2c68454fa0f32970be5d226d |
| institution | Directory Open Access Journal |
| issn | 1880-4276 1883-2148 |
| language | English |
| last_indexed | 2024-04-14T07:24:55Z |
| publishDate | 2018-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Arrhythmia |
| spelling | doaj.art-c18fedcf2c68454fa0f32970be5d226d2022-12-22T02:06:03ZengWileyJournal of Arrhythmia1880-42761883-21482018-04-0134214815710.1002/joa3.12024Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trialYukihiko Yoshida0Masato Watarai1Kenshi Fujii2Wataru Shimizu3Kazuhiro Satomi4Yasuya Inden5Yoshimasa Murakami6Masato Murakami7Atsushi Iwasa8Masaomi Kimura9Nobuko Yamada10Tomofumi Nakagawa11Matias Nordaby12Ken Okumura13Department of Cardiology Japanese Red Cross Nagoya Daini Hospital Nagoya Aichi JapanDepartment of Cardiology Aichi Prefectural Welfare Federation of Agricultural Co‐operative Associations Anjo‐kosei Hospital Anjo Aichi JapanCardiovascular Division Sakurabashi Watanabe Hospital Osaka JapanDepartment of Cardiovascular Medicine Nippon Medical School Hospital Bunkyo‐ku Tokyo JapanDepartment of Cardiology Tokyo Medical University Shinjyuku‐ku Tokyo JapanDepartment of Cardiology Nagoya University Hospital Nagoya Aichi JapanDivision of Cardiology Nagoya City East Medical Center Nagoya Aichi JapanDepartment of Cardiology Shonan Kamakura General Hospital Kamakura Kanagawa JapanDepartment of Cardiology New Tokyo Hospital Matsudo Chiba JapanDepartment of Cardiology and Nephrology Hirosaki University Hospital Hirosaki Aomori JapanNippon Boehringer Ingelheim Co., Ltd. Shinagawa‐ku Tokyo JapanNippon Boehringer Ingelheim Co., Ltd. Shinagawa‐ku Tokyo JapanBoehringer Ingelheim Pharma GmbH & Co. KG Ingelheim am Rhein GermanyDivision of Cardiology Saiseikai Kumamoto Hospital Kumamoto JapanAbstract Background There are limited data on uninterrupted anticoagulation with direct oral anticoagulants during catheter ablation for atrial fibrillation (AF), particularly in Japan. We planned a subgroup analysis of the RE‐CIRCUIT study, comparing the use of uninterrupted dabigatran therapy with warfarin therapy during catheter ablation among the Japanese subgroup and with that in the total population. Methods The RE‐CIRCUIT study utilized a prospective, randomized, open‐label, blinded endpoint design, and the primary endpoint was the incidence of major bleeding events (MBEs). Patients were randomized to uninterrupted dabigatran 150 mg twice daily or warfarin. In this study, we analyzed the results in Japanese patients. Results Of 704 enrolled patients in the study, 112 Japanese patients were randomized to dabigatran (n = 65) or warfarin (n = 47). MBEs were experienced by two patients: one in the dabigatran group (1.6%, cardiac tamponade) and one in the warfarin group (2.2%, groin hematoma) (risk difference vs warfarin −0.6%; 95% CI −5.8, 4.7). Within the Japanese subgroup, there were no thromboembolic events in both groups. Conclusion While not designed to show statistical difference between two treatment groups, our results from the Japanese subgroup supported those from the overall population. Furthermore, this study provided clinical information regarding MBE, especially cardiac tamponade, in Japanese patients.https://doi.org/10.1002/joa3.12024catheter ablationdabigatranJapanesenonvalvular atrial fibrillationuninterrupted anticoagulation |
| spellingShingle | Yukihiko Yoshida Masato Watarai Kenshi Fujii Wataru Shimizu Kazuhiro Satomi Yasuya Inden Yoshimasa Murakami Masato Murakami Atsushi Iwasa Masaomi Kimura Nobuko Yamada Tomofumi Nakagawa Matias Nordaby Ken Okumura Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial Journal of Arrhythmia catheter ablation dabigatran Japanese nonvalvular atrial fibrillation uninterrupted anticoagulation |
| title | Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial |
| title_full | Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial |
| title_fullStr | Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial |
| title_full_unstemmed | Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial |
| title_short | Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial |
| title_sort | comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation results of the japanese subgroup of the re circuit trial |
| topic | catheter ablation dabigatran Japanese nonvalvular atrial fibrillation uninterrupted anticoagulation |
| url | https://doi.org/10.1002/joa3.12024 |
| work_keys_str_mv | AT yukihikoyoshida comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT masatowatarai comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT kenshifujii comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT watarushimizu comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT kazuhirosatomi comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT yasuyainden comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT yoshimasamurakami comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT masatomurakami comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT atsushiiwasa comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT masaomikimura comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT nobukoyamada comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT tomofuminakagawa comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT matiasnordaby comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial AT kenokumura comparisonofuninterruptedanticoagulationwithdabigatranetexilateorwarfarinintheperiproceduralperiodforatrialfibrillationcatheterablationresultsofthejapanesesubgroupoftherecircuittrial |